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Abstract
Background: Interleukin-9 (IL-9) was discovered as a helper T cell growth factor. It has long been recognized as an
important regulator in allergic inflammation. Recent years it was discovered to induce cell growth and
differentiation of multiple transformed cells. However, its oncogenic activities in B-cell lymphomas have not been
reported in detail.
Methods: Serum levels of IL-9 in DLBCL patients were quantified by ELISA, and its clinical significance was analysed.
The expression of IL-9 receptor (IL-9R) was investigated in lymphoma cell lines by RT-PCR and western blot,
respectively. In DLBCL cell lines LY1 and LY8, IL-9R genes were knocked down by RNA interference and stable
transfected cells were selected with puromycin. Normal and final siIL-9R (and siControl) LY1 and LY8 cells were
treated with IL-9 alone and in synergy with chemotherapeutic drugs. Cell proliferation and apoptosis were assessed
by Brdu incorporation and flow cytometric analysis. The mRNA of apoptosis regulation genes were measured with
real-time PCR.
Results: Elevated serum levels of IL-9 were detected in DLBCL patients (24/30) compared to healthy controls (0/15).
Positive expression of IL-9 (defined as a serum level ≥1 pg/ml) was correlated with lower serum albumin levels and
high international prognostic index (IPI) scores. IL-9R was expressed in both mRNA and protein levels in the five
lymphoma cell lines, including LY1, LY8, MINO, SP53 and Jurkat. In vitro studies showed that IL-9 directly induced
proliferation and inhibited apoptosis in LY1 and LY8 cells. It protects LY1 and LY8 cells from prednisolone induced
apoptosis, and promotes their proliferation that were inhibited by rituximab, vincristine and prednisolone. Its
molecular mechanism may be concerned with upregulating expression of p21CIP1 gene. Knock-down of IL-9R
gene could reverse the effects of IL-9 on LY1 and LY8 cells.
Conclusions: IL-9 is associated with clinical features of DLBCL patients. It promotes survival of DLBCL cells and
reduces the sensitivities of tumor cells to chemotherapeutic drugs via upregulation of p21CIP1 genes.
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Background
Diffuse large-B-cell lymphoma (DLBCL) is the most com-
mon form of non-Hodgkin’s lymphoma (NHL) in adults.
It accounts for about 30 % of total NHL cases with an an-
nual incidence of 7–8 cases per 100, 000 of the population
[1, 2]. Standard chemotherapy with cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP) has
helped over 40 % of DLBCL patients achieve long-term
survival. The addition of rituximab to the CHOP regimen
increased the 5-year overall survival to nearly 60 %.
Although tremendous progress has been made in the out-
comes of DLBCL, approximately one third of patients died
from drug resistance or from relapse [3]. The unclear mo-
lecular etiology of the disease limits further development
of DLBCL therapy.
The biologic processes that lead to lymphomagenesis
are complex and seem to be different among lymphoma
histotypes. It has been widely acknowledged that immune* Correspondence: xinw007@126.com
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system dysfunction plays a crucial role in the pathogenesis
of lymphoma [4, 5]. Abnormal production of cytokines,
which serve crucial regulatory roles in host immunity,
accompany the onset of certain lymphomas [6]. The cyto-
kine IL-9 was initially described as a growth factor se-
creted by activated Th2 cells. It acts through a γC-family
receptor on target cells and has diverse functions in im-
mune and inflammatory responses [7–9]. Recently, the de-
termination of the growth-promoting and anti-apoptotic
activities of IL-9 in multiple transformed cell lines
suggests a potential role of IL-9 in tumorigenesis [10].
Dysregulated expression of IL-9 was detected in select
sub-populations of Hodgkin’s Disease (HD) and nasal nat-
ural killer (NK)/T-cell lymphoma patients [11, 12]. Experi-
mental analysis of tissue sections also demonstrated a
unique association between IL-9 expression and the devel-
opment of HD and anaplastic large cell lymphoma
(ALCL) [13]. However, the oncogenic activities of IL-9 in
lymphomas derived from B-cell lineages have not been re-
ported in detail.
Our previous study demonstrated that there was an
elevated serological level of IL-9 in some B-cell NHL pa-
tients (including several DLBCL cases). Neutralizing IL-
9 with certain specific antibodies inhibited tumor growth
in murine models of B-cell lymphoma [14]. Conse-
quently, we formally considered the possibility that IL-9
might contribute to the development of DLBCL. In an
attempt to validate this hypothesis, we examined the ex-
pression of IL-9 in the sera of DLBCL patients, and
demonstrated the effect of IL-9 on the biological behav-
ior of DLBCL cell-lines in vitro.
For the first time, we provide convincing evidence of
the participation of IL-9 in DLBCL and offer the notion
that specific silencing of the IL-9R gene may serve a po-




Blood samples from 30 DLBCL patients were taken at diag-
nosis while sera from 15 healthy volunteers served as nor-
mal controls. Clinical information of the enrolled DLBCL
patients, including sex, age, International Prognostic Index
(IPI) score, serum levels of lactate dehydrogenase (LDH),
albumin and β2 microglobulin, were also collected. All
DLBCL cases were diagnosed between January 2010 and
May 2014 according to the WHO criteria [15].
ELISA for IL-9
Serum samples from 30 DLBCL patients and 15
healthy volunteers were collected and frozen at −80 °C.
Serological levels of IL-9 were quantified using a
human ELISA kit (eBioscience) according to the manu-
facturer’s instructions.
Cell culture
The human DLBCL cell-lines LY1 and LY8 [16] were cul-
tured in IMDM supplemented with 10 % fetal bovine
serum. The two human mantle cell lymphoma (MCL) cell-
lines Mino and SP53 (a kind gift from Dr. Michael Wang,
Department of Lymphoma and Myeloma, The University
of Texas, MD Anderson Cancer Center), the human acute
T cell Leukemia cell-line Jurkat, and the human myeloma
cell-line RPMI8226 (obtained from the China Center for
Type Culture Collection) were maintained in RPMI-1640
medium supplemented with 10 % FBS. Stable transfected
cells were grown in IMDM supplemented with puromycin
(2 g/mL) and 10 % FBS. All cell-lines were incubated at 37 °
C in an atmosphere containing 5 % CO2.
Western blot analysis
The expression of IL-9R in five lymphoma cell lines was
determined by Western blot analysis. Total protein was
extracted by RIPA and 1 % PMSF. The protein concen-
trations were determined by the BCA assay. Cell lysates
were then resolved by electrophoresis on a 10 % SDS-
polyacrylamide gel and electro-transferred onto nitrocel-
lulose membranes. After the membranes were blocked
with 5 % skim milk non-fat proteins in Tris-saline buffer
that was supplemented with 0.1 % Tween-20, they were
subsequently probed with primary antibodies (i.e., rabbit
anti-IL-9Rα polyclonal antibody, 1:100, Abcam, and
mouse anti-β-actin monoclonal antibody, 1:10,000;
Abcam) at 4 °C overnight. After washing with TBST, sec-
ondary antibody that was conjugated with horseradish
peroxidase (1:8000), was added to the membranes. Sub-
sequently, proteins were detected by an enhanced
chemiluminescence detection kit (Millipore).
Reverse transcription PCR and real-time quantitative PCR
Total RNA was extracted from the cell lines using Trizol
reagent (Invitrogen) according to the manufacturer’s in-
structions. Reverse transcription was performed using
the PrimeScript RT (reverse transcription) reagent Kit
(TaKaRa). The expression of IL-9R mRNA in lymphoma
cell lines was detected by RT-PCR with the cycling pa-
rameters defined as follows: an initial cycling for 5 min
at 94 °C, followed by 40 cycles of 15 s at 95 °C, 30 s at
59 °C and 55 s at 72 °C. PCR products were confirmed
as a single product of the desired size on agarose gels
and visualized by ethidium bromide (EtBr) staining.
In addition, the changes in the mRNA levels for MYC,
BAX, p21CIP1, PIM1, BCL2L1 and MCL1 after IL-9 treat-
ment were measured by using real-time quantitative PCR
with a SYBR Premix Ex Taq Kit (TaKaRa). Samples were
run in triplicate under standard conditions (95 °C for 30 s
followed by 40 cycles at 95 °C for 5 s and 65 °C for 15 s) in
a Roche 480 instrument. The relative expression of each
gene was quantified by using β-actin expression as an
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endogenous control. Dissociation curves were performed
after each experiment to confirm the specificity of product
amplification. The data collated for mRNA relative fold in-
crease was analyzed using untreated cells as a reference
control. Specific primers for the PCR assay were obtained
from Biosune, and the primer sequences are shown in
Table 1.
Knockdown of IL-9R by lentivirus-mediated RNA
interference
Knockdown of the IL-9R gene was carried out by
lentivirus-mediated RNA interference. Oligonucleotides
coding for the short hairpin RNA (shRNA) targeting
human IL-9R (with a target sequence of 5′-
GCTCGTGCCATCTGACAATTT-3′) were annealed
and inserted into the pLK-GFP-puro vector (Shanghai
Telebio company, China). The empty pLK-GFP-puro
vector was employed as a negative control. The pLK-
shRNA and control vector were then transfected into
HEK293 cells, together with second generation pack-
aging plasmids (i.e., pRsv-REV, pMDlg-pRRE, pMD2G).
Virus supernatant was collected 72 h after transfection.
LY1 and LY8 cells were infected with the IL-9R-RNAi or
negative control lentivirus at a multiplicity of infection
(MOI) of 80. The stably infected cells were selected with
puromycin (5 g/mL) for 2 weeks to obtain final siIL-9R
and siControl LY1 and LY8 cells. The efficiency of IL-9R
knockdown was assessed by both real-time PCR and
Western blot analysis (Additional file 1: Figure S1).
Cell treatment
To test the direct influence of IL-9 on DLBCL cells, LY1
and LY8 cells were cultured dose-dependently with IL-9
(0, 20, 40, 60 and 80 ng/mL) for 72 h, following which, cel-
lular apoptosis was analyzed by flow cytometry. Moreover,
cell proliferation was also tested after LY1 and LY8 cells
were treated with IL-9 (80 ng/mL) for 72 h.
To determine the effect of IL-9 on the responses of
DLBCL cells to chemotherapeutic drugs, stably trans-
fected (i.e., siIL-9R and siControl) LY1 and LY8 cells were
exposed to prednisone (100 ug/ml), rituximab (10 ug/ml)
and vincristine (0.8 ng/ml) either in the presence or ab-
sence of IL-9 (80 ng/mL) for 72 h. After these interven-
tions, cell proliferation and apoptosis were evaluated by
BrdU incorporation and FACS analysis, respectively.
Flow cytometric analysis of cell apoptosis
Cell death was measured by flow cytometry using an
annexin V- FITC and propidium iodide (PI) apoptosis
detection kit (KeyGEN BioTECH) according to the manu-
facturer’s instructions. Briefly, 105 to 5 × 105 cells were in-
cubated with annexin V-FITC and PI for 10 min at room
temperature in the dark. Cells were then immediately ana-
lyzed using a FACScan flow cytometer (BD Biosciences).
Viable cells were not stained with annexin V-FITC or PI,
while by contrast, necrotic cells were stained annexin V-
FITC and PI positive, whereas apoptotic cells were stained
annexin V-FITC-positive and PI-negative [17, 18].
Cell proliferation assays
Cell proliferation was tested by BrdU incorporation.
Cells were grown at a density of 1 × 105/ml in 96-well
plates. After 72 h of treatment, cell proliferation was
measured using the BrdU Cell Proliferation ELISA
(Roche) according to the manufacturer’s protocols. The
absorbance of each well was determined at a wavelength
of 450 nm using an automated microplate reader.
Statistical analysis
The numerical data were presented as mean ± SD. All
statistical analyses were performed by using the statistics
software program SPSS version 16.0 for Windows.
Independent-sample T test was used to analyze numer-
ical variables. Non-parametric data and comparative
analysis between both groups of patients with different
IL-9 expression were evaluated by Chi-square analysis
and Fisher’s exact test. Statistically significant differences
were defined at an alpha value of P < 0.05.
Results
Upregulated serological IL-9 of DLBCL patients and its
correlation with clinical characteristics
To investigate the possible involvement of IL-9 in DLBCL,
we compared serum levels of IL-9 in patients with DLBCL
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and healthy controls (Fig. 1). If the serum IL-9 level ≥1 pg/
ml was defined as positive expression, IL-9 was detected
in 24 of 30 sera from DLBCL patients (mean concentra-
tion 1.43 ± 0.64 pg/ml) while no serum samples from
healthy volunteers contained marginally detectable levels
of IL-9 (0.82 ± 0.15 pg/ml). Fisher’s exact test revealed sig-
nificant differences between both groups (p = 0.003).
In addition, the clinical characteristics between
DLBCL patients with different IL-9 expressions were
also compared. As shown in Table 2, there were no dif-
ferences in age (P = 0.848) and sex (P = 0.678) between
groups. The association between positive IL-9 expression
(concentration ≥1 pg/ml) and serum levels of LDH
(506.3 vs 279.2 u/L, P = 0.945) and β2 microglobulin
(2.35 vs 1.8 ug/ml, P = 0.202) was also not statistically
significant. Nevertheless, patients with positive IL-9 ex-
pression showed a lower serum albumin level (35.85 ±
3.65 vs 41.8 ± 2.12 g/L, P = 0.009). The international
prognostic index (IPI) score, which is the most
important prognostic indicator, was higher in IL-9 posi-
tive cases compared with IL-9 negative cases (P < 0.001).
IL-9R expressed in lymphoma cell lines
In our previous study, immunohistochemical analysis
showed that the IL-9R protein was located on the mem-
brane of tumor cells within DLBCL tissues. Overexpres-
sion of IL-9R protein was correlated with serum lactic
dehydrogenase (LDH) levels, clinical stage and a high
Ki-67 labeling index in DLBCL patients [19]. Concord-
ant with in vivo observations, the expression of IL-9R in
lymphoma cell-lines was confirmed by RT-PCR and
western blot analysis, respectively. IL-9R expression was
demonstrated for both mRNA and protein levels within
the five lymphoma cell-lines, including LY1, LY8, MINO,
SP53 and Jurkat (Fig. 2). The myeloma cell-line
RPMI8226 served as a negative control.
IL-9 directly induced proliferation and inhibited apoptosis
in DLBCL cells
To determine whether IL-9 activated intracellular sig-
nals, we treated LY1 and LY8 cells with IL-9 at different
concentrations. As shown in Fig. 3, the apoptosis of LY1
and LY8 cells was dose-dependently reduced upon ex-
posure to IL-9. At a concentration of 80 ng/mL, IL-9 de-
creased cellular apoptosis to approximately 70 and 50 %
of the baseline levels in LY1 and LY8 cells, respectively.
Besides, the proliferative responses of LY1 and LY8 cells
in response to IL-9 were also assessed by measuring BrdU
incorporation after 3 days of culture. Direct IL-9 treat-
ment (80 ng/ml) of DLBCL cells displayed a marked in-
crease in proliferation (Fig. 4). LY1 and LY8 cells showed
an approximate 20 % increase in BrdU incorporation.




IL-9 expression in sera P value
Negative (%) Positive (%)
Age (y) 57 55 0.776a
Sex 0.678b
Male 4 (50) 14 (63.6)
Female 4 (50) 8 (36.4)
Serum LDH level 279.2 506.3 0.945a
Serum β2 microglobulin level 1.8 2.35 0.202a
Serum albumin level 41.8 35.8 0.009a
IPI score
0 6 (75) 0 <0.001b
1 0 0
2 0 10 (62.5)
3 2 (25) 2 (12.5)
4 0 4 (25)
a: Student’s t test t-test. b : Fisher’s exact test
Fig. 1 Serum levels of IL-9 were higher in DLBCL patients (1.43 ±
0.64 pg/ml) than healthy controls (0.82 ± 0.15 pg/mL). If IL-9 concentration
≥1 pg/ml was defined as positive expression, Fisher’s exact test revealed
significant differences between the two groups (p= 0.003)
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IL-9 protects DLBCL cells from prednisolone induced
apoptosis
Stably transfected (siIL-9R and siControl) LY1 and LY8
cells were incubated with prednisolone (100ug/ml) for 72 h
either in the presence or absence of IL-9 (80 ng/mL). Cell
viability was measured by FACS after double-staining with
annexinV and PI. As indicated in Fig. 5, the exposure to
prednisone induced a significant cellular apoptosis in both
siControl LY1 and LY8 cells; moreover, this process was al-
most completely inhibited by IL-9. However, in siIL-9R
cells, whose IL-9R gene was silenced by RNA interference,
the anti-apoptotic activity of IL-9 was not obvious.
IL-9 promotes proliferation that was inhibited by
chemotherapeutic drugs
Stable transfected siControl LY1 and LY8 cells were ex-
posed to prednisone (100ug/ml), rituximab (10ug/ml)
and vincristine (0.8 ng/ml) for 72 h and then cell prolif-
eration was evaluated. As shown in Fig. 6, all three drugs
obviously inhibited cell proliferation. When we treated
cells with IL-9 synergistically, the killing effect by che-
motherapeutic drugs was weakened. However, in siIL-9R
cells, the drug resistance that was induced by IL-9 was
alleviated.
IL-9 augments p21CIP1 expression in DLCBL cells
To gain further insights into the molecular mechanism by
which IL-9 promoted survival of DLBCL cells, we treated
LY1 and LY8 cells with IL-9 (80 ng/ml) for 72 h and then
we investigated the differential changes in expression of
six JAK-STAT downstream regulatory genes, including
MYC, BAX [20], p21CIP1, PIM1 [21, 22], BCL2L1 and
MCL1 [23]. We analyzed data of mRNA fold increases
using untreated cells as a reference control. As shown in
Fig. 7, the mRNA expression of p21CIP1 was upregulated
by two-fold in LY1 cells and by more than three-fold in
LY8 cells. The expression changes of PIM1 genes were dif-
ferent in LY1 and LY8 cells. It amplified to 2 folds in LY1
cells and remained unchanged in LY8 cells. There were no
significant changes in mRNA expression of anti-apoptosis
genes including MYC, BAX, BCL2L1 and MCL1.
Discussion
The biologic processes that lead to lymphomagenesis are
complex and seem to be different among lymphoma his-
totypes. Numerous cytokines are believed to take part in
this process [24, 25].
The dysregulated expression of IL-9 has been detected
in biopsies or serum specimens of patients with some
malignant lymphomas, such as HD, ALCL and NKT-cell
lymphoma, which provides clinical evidence for its pos-
sible involvement in lymphomagenesis [13]. However,
the pathogenic role of IL-9 in lymphomas derived from
B-cell lineages has not been previously reported. In our
previous study, IL-9 was demonstrated to take part in
the pathogenesis of B-cell NHL by augmenting the ex-
tent of immunosuppression that is mediated by Treg
Fig. 2 The expressions of IL-9R in lymphoma cell lines were tested
by RT-PCR and western blot. All the five lymphoma cell lines (LY1,
LY8, MINO, SP53 and Jurkat) were detected to express IL-9R in both
mRNA and protein levels. Myeloma cell line RPMI8226 served as
negative control
Fig. 3 a LY1 cells. b LY8 cells. *The cell apoptosis at this IL-9 concentration was statistically significant compared to untreated cells (IL-9 concentration
is 0). Cell apoptosis between groups at different IL-9 concentrations had statistical significance. This means that the apoptosis of LY1 and LY8 cells was
dose-dependently reduced upon exposure to IL-9. IL-9 at a concentration of 80 ng/mL decreased cell apoptosis to approximately 70 % and 50 % of
the baseline levels in LY1 and LY8 cells, respectively
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cells and mast cells [14]. Based upon these results, we
attempt to demonstrate that IL-9 plays a direct role in
the survival of DLBCL cells.
Our studies indicate that serum levels of IL-9 are ele-
vated in patients with DLBCL. The positive sera IL-9 ex-
pression is associated with some clinical parameters,
including high IPI scores and low serum levels of albu-
min. High IPI means worse disease prognosis and low
serum levels of albumin is usually connected with more
severe disease consumption. These results imply that
high serumal IL-9 levels may be correlated with more
tumor burden.
In this study, we don’t analyse the exact source of IL-
9. In fact, some studies have confirmed that IL-9 could
act in an autocrine manner in ALCL and NKT-cell
lymphomas [13]. Meanwhile, many researchers believe
that certain immune cells, including Tregs, mast cells,
Th7 and Th17 cells, could produce IL-9 [26]. Here, we
think that the elevated IL-9 levels might be secreted by
DLBCL cells themselves, and might also be produced by
the non-malignant infiltrating cells within tumor tissues.
Nevertheless, whatever source of IL-9 in the serum of
patients, the correlation between augmented IL-9 levels
and the more severe disease state provides direct clinical
evidence for the contribution of IL-9 to the pathogenesis
of DLBCL.
Since there was an upregulation of IL-9 in the sera of
patients with DLBCL, we investigated the expression of
IL-9R in DLBCL tissues and cell-lines to explore the ac-
tions of IL-9 on DLBCL cells. The IL-9R is comprised of
a cytokine-specific α-chain and a common γ-chain,
which is shared with IL-2, IL-4, IL-7, IL-15 and IL-21.
The effects of IL-9 on target cells were mainly
dependent on its high-affinity binding with the IL-9R.
In our previous study, nearly 70 % of DLBCL cases
examined stained positive for IL-9R by immunohisto-
chemistry. Malignant DLBCL cells in tissue sections
were confirmed by pathologists, and IL-9R was lo-
cated on the surface of these tumor cells [19]. As
shown by in vitro studied herein, the expression of
IL-9R was detected at both the mRNA and protein
levels within the five lymphoma cell-lines, including
the DLBCL cell-lines LY1 and LY8, mantle cell
lymphoma (MCL) cell-lines Mino and SP53, as well
as the human acute T cell leukemia cell-line Jurkat.
This may imply that the tumorigenic effect of IL-9
also exists in other types of lymphoma.
To examine the direct influence of IL-9 on DLBCL
cell-lines, we treated LY1 and LY8 cells with exogenous
rhIL-9 in vitro. The result indicates that there is a
concentration-dependent decrease in cell apoptosis on
both LY1 and LY8 cells. At the same time, a pro-
proliferative activity of IL-9 was also observed after the
intervention. These observations are consistent with
clinical findings and provide direct evidence that IL-9
can promote the survival of DLBCL cells.
Since IL-9 plays a direct anti-apoptotic and pro-
proliferative effect on DLBCL cells, we have considered
the possibility that IL-9 might dampen the sensitivities
of DLBCL cells to chemotherapeutic drugs. To examine
Fig. 4 The proliferative activities were assessed by brdu incorporation. Direct IL-9 treatment on both LY1 and LY8 cells displayed statistically enhancement
at absorbance of 450 nm
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the validity of this hypothesis, siControl LY1 and LY8
cells were exposed to prednisone, vincristine and rituxi-
mab in synergy with IL-9. The cytotoxic effect of vincris-
tine on lymphoma cells is usually performed through
inhibition of cell proliferation [27] and similar actions
are also possessed by rituximab [28] and prednisone.
Our studies demonstrated that the inhibited cell prolifer-
ation by these chemotherapeutic drugs was reversed by
IL-9. Analysis of cell apoptosis reveals that IL-9 protects
DLBCL cells from prednisone-induced apoptosis. These
findings indicate that the lymphomagenic activity of IL-9
is still valid in the presence of chemotherapeutic drugs.
On account that the effects of IL-9 on target cells are
dependent on the high-affinity binding of IL-9 with its
receptor, we attempted to knockdown the IL-9R gene by
RNA interference. The results display that silencing of
the IL-9R gene alleviates the drug resistance that is in-
duced by IL-9, which provides a potential therapeutic
target in DLBCL.
Our previous experiments have demonstrated that IL-9
promoted the survival of DLBCL cells. The signal transduc-
tion mediated by IL-9 and its receptor is mainly dependent
on the JAK/STAT pathway [29, 30]. To gain further insight
into the molecular mechanism of IL-9, we measured ex-
pression of its downstream genes. Real time RT-PCR re-
vealed augmented levels of p21CIP1 genes in both LY1 and
LY8 cells due to exposure to IL-9.
P21CIP1 is a cell-cycle regulatory protein that inter-
acts with the cyclin-dependent kinases (CDK) CDK2 and
CDK4 [31]. Moreover, P21CIP1 promotes the assembly
of active cyclin D1/CDK complexes and stimulates cell
cycle progression [32]. Enhanced expression of p21CIP1
provides a potential explanation for the pro-proliferative
and anti-apoptotic activities of IL-9.
Conclusions
In conclusion, our findings showed that serum levels
of IL-9 were elevated in DLBCL patients and positive
Fig. 5 a.c LY1 cells. b.d LY8 cells. In both sicontrol LY1 and LY8 cells, IL-9 reduced apoptosis induced by prednisone. If IL-9R gene was knockdown by
RNA interference, this protective effect was weakened
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expression of IL-9 was correlated with adverse prog-
nosis indicators. It directly effected proliferation and
apoptosis of DLBCL cells by enhancing the expression
of p21CIP1 genes and promoted tumor cells to dis-
play resistance to chemotherapeutic drugs. Knock-
down of the IL-9R gene by RNA interference reversed
the lymphomagenic activities of IL-9 on DLBCL cells.
These observations contribute to our understanding
of the cause and resistance mechanisms of DLBCL,
and provide a potential targeted therapeutic approach
for DLBCL.
Additional file
Additional file 1: Figure S1. IL-9R gene was knockout using lentivirus-
mediated RNA interference. The efficiency of IL-9R knockdown was assessed
by western blot analysis. The expression of IL-9R protein was obvious decreased
in siIL-9R cells than sicontrol cells. (TIF 206 kb)
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Fig. 7 a LY1 cells. b LY8 cells. IL-9 influences the expression changes of
apoptotic genes in DLBCL cells. The mRNA expression of p21CIP1 was
upregulated by IL-9 to 2 folds in LY1 cells and more than 3 folds in LY8
cells. There were no significant changes of mRNA expression in anti-
apoptosis genes including MYC, BAX, BCL2L1 and MCL1. The expression
changes of PIM1 genes were different in LY1 and LY8 cells. It amplified
to 2 folds in LY1 cells and remained unchanged in LY8 cells
Fig. 6 a LY1 cells. b LY8 cells. In siControl cells, the reduced cell proliferations induced by vincristine, prednisone and rituximab could be reversed
by IL-9. The pro-proliferative effect was not obvious in siIL-9R cells
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